SK Biopharmaceuticals Co., Ltd. (KRX:326030)
South Korea · Delayed Price · Currency is KRW 89,100
+700 (0.79%)
Last updated: Jun 4, 2026, 9:55 AM KST
SK Biopharmaceuticals Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 348,808 | 266,950 | 240,738 | -32,883 | -139,431 | 64,846 |
Depreciation & Amortization | 16,249 | 16,947 | 17,428 | 15,317 | 12,984 | 11,642 |
Loss (Gain) From Sale of Assets | 194.8 | 194.81 | -171.02 | 18.72 | 11.28 | 3.02 |
Asset Writedown & Restructuring Costs | -597.33 | -597.33 | - | 6,808 | 172.96 | - |
Loss (Gain) From Sale of Investments | -7,475 | 2,757 | 1,396 | -12,243 | 2,858 | -2,208 |
Loss (Gain) on Equity Investments | 32,764 | 34,307 | 31,253 | 11,535 | 14,927 | 34,544 |
Stock-Based Compensation | -662.72 | 3,633 | 7,511 | 3,233 | 60.66 | 416.71 |
Other Operating Activities | -105,316 | -111,576 | -170,591 | -10,345 | 14,161 | -132,402 |
Change in Accounts Receivable | -105,252 | -58,344 | -37,064 | -52,456 | -13,169 | -41,610 |
Change in Inventory | 22,160 | 10,880 | -8,593 | -13,708 | -38,693 | -29,459 |
Change in Accounts Payable | -9,616 | 6,036 | 940.7 | -20,711 | 6,965 | 607.69 |
Change in Other Net Operating Assets | -24,291 | 5,144 | 12,053 | 11,232 | -20,767 | 748.38 |
Operating Cash Flow | 166,965 | 176,334 | 94,900 | -94,201 | -159,920 | -92,872 |
Operating Cash Flow Growth | 67.36% | 85.81% | - | - | - | - |
Capital Expenditures | -8,186 | -6,892 | -1,395 | -2,385 | -4,911 | -4,316 |
Sale of Property, Plant & Equipment | - | - | - | - | - | 11.24 |
Cash Acquisitions | - | - | - | 31,043 | - | - |
Sale (Purchase) of Intangibles | -23,290 | -22,119 | -10,726 | -864.17 | -1,050 | -1,676 |
Investment in Securities | -6,380 | -4,367 | 3,506 | 198,587 | -89,691 | 265,618 |
Other Investing Activities | -3,054 | -2,068 | -2,340 | -1,104 | -10.78 | -639.56 |
Investing Cash Flow | -40,972 | -35,420 | -10,941 | 225,273 | -95,714 | 258,971 |
Short-Term Debt Issued | - | 6.94 | 100,000 | - | - | - |
Long-Term Debt Issued | - | - | - | - | 141,751 | - |
Total Debt Issued | 6.94 | 6.94 | 100,000 | - | 141,751 | - |
Short-Term Debt Repaid | - | -50,007 | -50,000 | - | - | - |
Long-Term Debt Repaid | - | -106,678 | -54,498 | -5,575 | -5,477 | -4,827 |
Total Debt Repaid | -81,890 | -156,685 | -104,498 | -5,575 | -5,477 | -4,827 |
Net Debt Issued (Repaid) | -81,883 | -156,678 | -4,498 | -5,575 | 136,274 | -4,827 |
Other Financing Activities | -6,284 | - | 0.38 | 12,198 | -1,360 | 180.69 |
Financing Cash Flow | -88,167 | -156,678 | -4,498 | 6,623 | 134,914 | -4,646 |
Foreign Exchange Rate Adjustments | 4,219 | 727.94 | 3,646 | -2,054 | -1,143 | 5,135 |
Miscellaneous Cash Flow Adjustments | -0 | - | - | - | - | 0 |
Net Cash Flow | 42,046 | -15,036 | 83,107 | 135,640 | -121,863 | 166,589 |
Free Cash Flow | 158,779 | 169,442 | 93,505 | -96,586 | -164,831 | -97,188 |
Free Cash Flow Growth | 61.43% | 81.21% | - | - | - | - |
Free Cash Flow Margin | 20.09% | 23.97% | 17.08% | -27.22% | -66.96% | -23.21% |
Free Cash Flow Per Share | 2026.84 | 2163.64 | 1193.98 | -1233.34 | -2104.77 | -1241.01 |
Cash Interest Paid | 5,113 | 6,444 | 9,499 | 8,142 | 3,488 | 844.19 |
Cash Income Tax Paid | 20,392 | 20,035 | 12,154 | 8,126 | 4,681 | 6,160 |
Levered Free Cash Flow | 75,879 | 112,028 | 33,476 | -54,562 | -108,210 | 51,274 |
Unlevered Free Cash Flow | 79,913 | 116,834 | 40,152 | -49,387 | -105,888 | 51,865 |
Change in Working Capital | -116,999 | -36,283 | -32,663 | -75,643 | -65,664 | -69,713 |